USE OF ALTERNATIVE THERAPY, QUALITY OF LIFE, AND HEALTHCARE SPENDING IN CHINESE PATIENTS WITH OSTEOARTHRITIS
ZHANG JX, WOO J1, LAU E2
1The Chinese University of Hong Kong, Shatin, Hong Kong; 2The Chinese University of Hong Kong, Shatin, NT, Hong Kong

OBJECTIVES: To describe the pattern of use of alternative therapy, healthcare spending, and health-related quality of life in Chinese osteoarthritis (OA) patients in Hong Kong. METHODS: We conducted a retrospective, cross-sectional study of 547 adult Chinese patients in Hong Kong who have been diagnosed as having OA. We defined the alternative therapy as 1 of the 11 therapies outlined in international publications. OA patients who used alternative therapies and those who did not were compared for their socio-economic status, disease profile, personal healthcare spending, and quality of life. Quality of life was measured using a Health Utility Index based upon SF-36 health surveys. We further investigated the association between the use of alternative therapies and personal healthcare spending, and its association with the Health Utility Index, in multivariate regressions controlling for socio-economic variables, years of OA, and the severity of OA. RESULTS: Of the 547 OA patients, 219 (38.2%) had used 1 or more of the 11 alternative therapies for OA. The most commonly used therapies, and the percentage of patients who used them, were acupuncture (21.4%), exercise (12%), herbal remedy (5.9%), lifestyle diets (5.8%), energy healing (4.4%), and chiropractic manipulation (3.8%). On average, payment for alternative therapies constitutes 5% of the overall personal healthcare spending, and 29% of the out-of-pocket payments. CONCLUSION: The use of alternative therapies was statistically significantly associated with higher personal healthcare spending, after adjusting for socio-economic variables, years of OA and severity of OA. The use of alternative therapies was not significantly associated with an improvement in quality of life in the regression analysis.
within the NSAID class and other therapeutic classes that constitute the analgesic market. METHODS: The study design was a retrospective study of paid pharmacy claims for analgesic medications for a continuously insured population of 62,614 members from July 1996 to June 2001. Claims were divided into seven therapeutic categories: hydrocodone, narcotics, non-narcotics, newer NSAIDs (Relafen, Daypro, Arthrotec), older NSAIDs, oxycodone, and COX-2 inhibitors. Data of paid analgesic pharmacy claims were analyzed by overall analgesic market prescription claims, day supply, pain management therapies, per diem cost (ingredient cost per day supply) and market share per therapeutic category. RESULTS: Over the 5-year period, claims increased 29.1% while day supply per claim increased 17.7% for a total growth in day supply of almost 52%. The proportion of the population who used an analgesic also increased from 33.4% in the first year to 37.9% in the fifth year. There was a 15% increase in people receiving at least one analgesic prescription in a year over the 5-year period. Per diem costs for the market increased from $1.74 in the first year to $2.20 in the fifth year. Per member per month costs increased 69.3% from $12.36 in the first year to $20.93 in the fifth year. COX-2 inhibitors market share by day supply increased from zero to 39.6%. The market share of the newer NSAIDs decreased from 20.5% in the year prior to the introduction of the COX-2 inhibitors (year 2) to 5.5% in the fifth year. CONCLUSIONS: Based on day supply, the analgesic market grew almost 52% with COX-2 inhibitors garnering 39.6% within 3 years of market introduction. The COX-2's benefited from both the growth in the market and reduction in market share of the newer NSAIDs.

ECONOMIC IMPLICATIONS OF NON-COMPLIANCE WITH OSTEOPOROSIS TREATMENT IN ACTUAL PRACTICE

Huybrechts K1, Caro J1, Ishak K2, Naujoks C3

1Caro Research Institute, Concord, MA, USA; 2Caro Research Institute, Dorval, QC, Canada; 3Novartis Pharma AG, Basel, Switzerland

OBJECTIVES: Although it is well recognized, in both clinical research and actual practice, that non-compliance with osteoporosis treatment is a problem, its economic implications have not been well documented. The objective of this study was to quantify the implications of non-compliance in terms of all-cause hospitalizations and total costs. METHODS: Demographic, prescription drug use, physician services and hospitalization information for women with osteoporosis who were dispensed an osteoporosis medication between 1996 and 2001 was obtained from the Saskatchewan Health data files. Subjects were considered to be compliant over a given period of time if they had medication available during 80% or more of that time interval. Hospitalization rates and total costs in various patient groups were compared using descriptive analyses. The impact of compliance was assessed further using regression analysis on the logarithmically transformed total cost, controlling for prior history of hospitalizations (which was considered a proxy for morbidity). RESULTS: A total of 11,249 women suffering from osteoporosis were identified with an average follow-up of 2.3 years. More than half (50.6%) did not have medication available to cover at least 80% of the time they were followed and were thus considered non-compliant. Overall, 48.5% of patients were hospitalized an average of 2.7 times during follow-up. Non-compliant patients were significantly more likely to be hospitalized (54.3%) than compliant patients (42.6%) (P < 0.0001). The total monthly cost—including both hospitalization and physician service costs—was significantly higher for non-compliant ($245 CAD) than for compliant ($214 CAD) patients (P < 0.05). The same trend was observed for both cost components individually. The effect of compliance on total cost was maintained after controlling for hospitalization history. CONCLUSION: The desired goal of keeping patients with osteoporosis on chronic treatment is not achieved adequately in actual practice and the cost implications of this behavior are substantial.

WITHDRAWN